GlassScriptPhysician profile
Leslie D Mccasland
NPI 1003873019
$8,571.16
in general payments reported to CMS, 2019-2025
23 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,999 · 2020: $264 · 2021: $206 · 2022: $424 · 2023: $698 · 2024: $955 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,579 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,579.06 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $4,068.75 | 2019 | |
| Amgen INC. | $981.14 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $908.64 | 2019-2025 | |
| Ucb, INC. | $368.11 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $365.67 | 2019-2025 | Tremfya |
| Pfizer INC. | $333.56 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $258.04 | 2019-2025 | |
| Glaxosmithkline, LLC. | $247.05 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $241.06 | 2019-2025 | Taltz |
| Horizon Therapeutics Plc | $160.40 | 2019-2022 | |
| Genentech USA, INC. | $147.72 | 2019-2023 | Actemra |
| Aurinia Pharma U.S., INC. | $70.61 | 2023-2024 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $60.67 | 2022-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.65 | 2023-2024 | Cyltezo, Ofev |
| Organon LLC | $60.65 | 2024-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $46.83 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $43.24 | 2025 | Orencia |
| Regeneron Healthcare Solutions, INC. | $42.84 | 2019 | |
| Mallinckrodt Hospital Products INC. | $42.75 | 2022-2025 | Acthar |
| Sandoz INC. | $23.83 | 2024 | Hyrimoz |
| Fresenius Kabi USA, LLC | $22.68 | 2025 | |
| Celgene Corporation | $16.27 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Mccasland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.